Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on April 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting...
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.81%. June E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.77%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM26...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.39%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.76%. June E-mini S&P futures (ESM26...
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER,...
FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome Additional indication for FILSPARI...
U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter ...
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets....
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting...